Evidence map›Paper›PMID 32577658›Full record

ArticlebioRxiv : the preprint server for biology2020

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.

Fabian Schmidt, Yiska Weisblum, Frauke Muecksch, Hans-Heinrich Hoffmann, Eleftherios Michailidis, Julio C C Lorenzi, Pilar Mendoza, Magdalena Rutkowska, Eva Bednarski, Christian Gaebler and 11 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 117 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Fabian SchmidtLaboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Yiska WeisblumLaboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Frauke MueckschLaboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Hans-Heinrich HoffmannLaboratory of Virology and Infectious Disease, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Eleftherios MichailidisLaboratory of Virology and Infectious Disease, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Julio C C LorenziLaboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Pilar MendozaLaboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Magdalena RutkowskaLaboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Eva BednarskiLaboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Christian GaeblerLaboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Marianna AgudeloLaboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Alice ChoLaboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Zijun WangLaboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Anna GazumyanLaboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Melissa CipollaLaboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Davide F RobbianiLaboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, 1230 York Avenue, New York NY 10028.
Rockefeller University · USHoward Hughes Medical Institute · US

Funding

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Understanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2014 to 2023
$26.0M
Overcoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS.R01AI078788 · NIAID · ROCKEFELLER UNIVERSITY · PI HATZIIOANNOU, THEODORA · 2008 to 2021
$9.3M
Type I interferon-stimulated genes and the antiviral immune responseR01AI091707 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2011 to 2020
$5.5M
Discovery and Mechanism of Antiretroviral FactorsR37AI064003 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2011 to 2020
$4.9M
NCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI078788NIAID NIH HHS R01 AI091707NIAID NIH HHS R37 AI064003NIAID NIH HHS U19 AI111825
6 · The paper itself

Abstract

The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARSCoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.

Identifiers

PMID32577658
PMCPMC7302213
OpenAlexW3034813551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.